Who is sponsoring NCT05252871?

NCT05252871 is sponsored by Western University of Health Sciences.

What condition does NCT05252871 study?

NCT05252871 studies Presbyopia.

Is NCT05252871 still recruiting?

NCT05252871 is currently completed. Last updated 15 August 2024.

Are results published for NCT05252871?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-08-15 · How we verify

NCT05252871

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessment of Three Basic Progressive Lens Designs

Completed NA Results posted Last updated 15 August 2024

What this trial tests

NA trial testing Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating in Presbyopia in 80 participants. Completed in 6 June 2022.

Timeline

9 December 2021

Primary endpoint
6 June 2022

6 June 2022

Quick facts

Lead sponsor	Western University of Health Sciences
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	80
Start date	9 December 2021
Primary completion	6 June 2022
Estimated completion	6 June 2022
Sites	1 location across United States

Drugs / interventions tested

Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating

Conditions studied

Presbyopia — all drugs for Presbyopia →

Sponsor

Western University of Health Sciences

Who can join

Adults 45 to 70, any sex, with Presbyopia. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Evaluate the Adaptation to Progressive Lens Designs. Primary · Entire study duration (approx. 4 weeks)

Evaluate the adaptation to progressive lens designs through a "Satisfaction questionnaire" after 1 week of use of each of the 3 progressive addition lenses. Scale titles: Visual Quality Scale: A 5-point scale from a minimum value of 1 to a maximum score of 5. Higher scores mean better outcomes.

Group	Value	95% CI
Experimental: The Specified PAL Design Wearers, Wearing Pair 1	4.125	± 0.822
The Other PAL Design Wearers, Wearing Pair 1	4.025	± 1.05
Experimental: The Specified PAL Design Wearers, Wearing Pair 2	3.875	± 0.992
The Other PAL Design Wearers, Wearing Pair 2	3.725	± 0.987
Experimental: The Specified PAL Design Wearers, Wearing Pair 3	4.300	± 0.939
The Other PAL Design Wearers, Wearing Pair 3	4.150	± 0.864

Evaluate the Immediate Preference Among Progressive Lens Designs. Secondary · Directly after receiving the lenses (approx. 15 minutes)

Evaluate the immediate preference for progressive lens designs through a "Satisfaction questionnaire" directly after receiving the 3 progressive addition lenses. Scale titles: Visual Quality Scale: A 5-point scale from a minimum value of 1 to a maximum score of 5. Higher scores mean better outcomes.

Group	Value	95% CI
Experimental: The Specified PAL Design Wearers, Wearing Pair 1	4.550	± 0.714
The Other PAL Design Wearers, Wearing Pair 1	4.400	± 0.709
Experimental: The Specified PAL Design Wearers, Wearing Pair 2	4.625	± 0.667
The Other PAL Design Wearers, Wearing Pair 2	4.450	± 0.783
Experimental: The Specified PAL Design Wearers, Wearing Pair 3	4.625	± 0.568
The Other PAL Design Wearers, Wearing Pair 3	4.400	± 0.672

Evaluate the Preference of Progressive Lens Designs. Secondary · Entire study duration (approx. 4 weeks)

Evaluate the final preference of progressive lens designs after wearing each of the 3 PALs for one week. Scale title: Preference of Progressive Addition Lenses Scale: "Pair 1", "Pair 2, "Pair 3"

Group	Value	95% CI
Experimental: The Specified PAL Design Wearers, Wearing Pair 1	11
The Other PAL Design Wearers, Wearing Pair 1	16
Experimental: The Specified PAL Design Wearers, Wearing Pair 2	10
The Other PAL Design Wearers, Wearing Pair 2	9
Experimental: The Specified PAL Design Wearers, Wearing Pair 3	19
The Other PAL Design Wearers, Wearing Pair 3	15

Sponsor's own description

This clinical trial investigates the differences between three different progressive addition lens designs. It is a non-invasive double-masked randomized clinical investigation. For this study, 80 participants will be recruited.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Progressive Additional Lenses (PAL), pre calibrated and made of polymeric material with anti-reflection coating

Trials testing the same drug.

NCT04734522 — Assessment of Progressive Lens Designs · NA · completed

Other recruiting trials for Presbyopia

Currently open trials in the same condition.

NCT07444658 — Performance of Two Daily Disposable Multifocal Contact Lenses · NA · recruiting
NCT07284966 — Comfort and Vision With TOTAL30 Multifocal Lenses · recruiting
NCT07077967 — Luminous Efficiency Function V(λ)' of Patients That Underwent Pseudophakic Presbyopic Corrections With EDOF IOLs · recruiting
NCT07113210 — Quality of Life in Presbyopic Patients Who Are Treated With Qlosi · Phase 4 · recruiting
NCT06948357 — Efficacy and Safety of BRIMOCHOL PF and CARBACHOL PF in Chinese Presbyopia Patients · Phase 2 · recruiting

Other Western University of Health Sciences trials

Trials by the same sponsor.

NCT07440030 — The Cervical "STRETCH" Study · NA · not yet recruiting
NCT06565065 — ImmunoBoost: The Lymphatic Osteopathic Manipulative Treatment Protocol Study · NA · recruiting
NCT06046183 — Resilience, Grit, and Stress in Medical Students · NA · unknown
NCT05454007 — Tracking Post-stroke Walking Improvements From the Clinic Into the Home · NA · recruiting
NCT05926245 — Topical Absorption of Glutathione-cyclodextrin Complex in Healthy Human Subjects Improves Immune Response Against Mycoba · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05252871 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Western University of Health Sciences
Last refreshed: 15 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05252871.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing